Statins are the first line of defense in the treatment of dyslipidemia and hypercholesterolemia illness. HMG-CoA reductase inhibitors or statins are the most widely prescribed drugs for persons at risk of cardiovascular disease. Cardiovascular disease (CVD) is the leading cause of death and a major cause of morbidity around the world. Statins have the same mechanism of action, but their chemical structures, pharmacokinetic profiles, and lipid-modifying potency differ. Triglycerides, cholesterol, and low-density lipoprotein (LDL) levels in the blood are all known risk factors for vascular disease, but statin drugs help to increase high-density lipoprotein (HDL) levels in our bloodstream. Some of the drugs utilized include rosuvastatin, atorvastatin, simvastatin, and pravastatin. According to clinical data, rosuvastatin is the most effective drug for decreasing low-density lipoprotein cholesterol and triglycerides, followed by atorvastatin, simvastatin and pravastatin. A brief review of the analytical methods developed from 2001-2021 for the estimation of Antilipidemic drugs has been discussed in the present study. This study will help the researchers to develop better methods for this class of drugs.